Disease-modifying antirheumatic drugs (DMARDs) are a gaggle of medicines commonly utilized in people with atrophic arthritis. A number of these drugs also are utilized in treating other conditions like Marie-Strumpell disease, rheumatoid arthritis, and systemic LE. The most recent drugs for the treatment of atrophic arthritis are the Janus kinase (JAK) inhibitors, which are FDA approved under the brand names Rinvoq, Olumiant and Xeljanz.